ReviewNeuropsychiatric disease and treatment2020
Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives.
Review in Neuropsychiatric disease and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials.Frontiers in psychiatry · 2024Pooled it
- Pooled it
- Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis.BMC pharmacology & toxicology · 2021Pooled it
- Trial
- Trial
- Cariprazine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder: A case report.Biomedical reports · 2026Article
- The potential role of kynurenine pathway and inflammation in pediatric obsessive-compulsive disorder with and without major depressive disorder comorbidity.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Review
- Modulation of glycine transporters as a novel therapeutic strategy in neuropsychiatry.Psychopharmacology · 2026Review
- Article
- Biological, Psychosocial, and Microbial Determinants of Childhood-Onset Obsessive-Compulsive Disorder: A Narrative Review.Children (Basel, Switzerland) · 2025Review
- Obsessive trajectories in children and adolescents exposed to adverse events (coronavirus disease 2019: global crisis teaches).Frontiers in psychology · 2025Review
- Remission of obsessive-compulsive disorder using ketogenic metabolic therapy in support of exposure and response prevention: a retrospective case report.Frontiers in psychiatry · 2025Article
- Psilocybin in pharmacotherapy of obsessive-compulsive disorder.Pharmacological reports : PR · 2024Review
- Unraveling the Boundaries, Overlaps, and Connections between Schizophrenia and Obsessive-Compulsive Disorder (OCD).Journal of clinical medicine · 2024Review
- A biophysical model for dopamine modulating working memory through reward system in obsessive-compulsive disorder.Cognitive neurodynamics · 2024Article
- Article
- Potential biomarkers and therapeutic targets for obsessive compulsive disorder: Evidences from clinical studies.Biochemia medica · 2024Review
- Spatiotemporal expression patterns of anxiety disorder-associated genes.Translational psychiatry · 2023Article
- SAPAP3, SPRED2, and obsessive-compulsive disorder: the search for fundamental phenotypes.Frontiers in molecular neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glutamate is a ubiquitous excitatory neurotransmitter, which is involved in normal physiology, a variety of central nervous system (CNS) functions, including excitotoxicity and neuronal migration. It is implicated in the pathogenesis of various neuropsychiatric disorders including epilepsy, Parkinson's disease, Alzheimer's dementia, schizophrenia and obsessive compulsive disorder (OCD). Over the years, a growing body of evidence has helped researchers understand the mechanisms underlying glutamatergic involvement in the pathogenesis of these disorders. In this review, we attempt to elucidate the role of glutamate in OCD, which is a chronic psychiatric condition with significant morbidity. This article provides current perspectives on the role played by glutamate in the pathogenesis, clinical symptoms and treatment response in OCD, a critical analysis of existing and emerging evidence, both clinical and preclinical, followed by a summary and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.